Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.57 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801564 | 1.00 | PTGDR2 (0.57) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1799871 | 0.95 | PTGDR2 (0.59) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1799873 | 0.95 | PTGDR2 (0.59) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1799875 | 0.95 | PTGDR2 (0.59) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL12617600 | 0.93 | PTGDR2 (0.54) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1801602 | 0.93 | PTGDR2 (0.54) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1801604 | 0.93 | PTGDR2 (0.54) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1799086 | 0.93 | PTGDR2 (0.63) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1801326 | 0.93 | PTGDR2 (0.63) | PTGDR2P2RY1MEN1KMT2A | |
| SCHEMBL1799087 | 0.93 | PTGDR2 (0.63) | PTGDR2P2RY1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951950-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951950-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951950-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20060241109-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241109-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGER2, PTGDR2, PTGER1 | PTGDR2 2/4885P2RY1 174/4885MEN1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.